SMARCB1 and synovial sarcoma: On the other end, C4 Therapeutics, Inc also discontinued phase 1 clinical trial of CFT8634 (NCT05355753), a potent and selective oral heterobifunctional degrader of BRD9 for the treatment of synovial sarcoma and SMARCB1-deleted tumors, since BRD9 degradation did not produce sufficiently effective results in patients.